blog.pahcenter.org — Italian researchers have reported that the drug bosentan has reduced the clinical decline in patients suffering from early stages of pulmonary arterial hypertension. Previous studies had shown that bosentan improved exercise capacity and pulmonary vascular resistance (PVR) and slowed clinical decline in patients with later stages of PAH.